1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,036 | 1,120 | 29.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.10. | MaaT Pharma Receives FDA Feedback Following Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors | 398 | Business Wire | Positive pre-Investigational New Drug (pre-IND) interaction with the Food Drug Administration (FDA) on Chemistry, Manufacturing and Controls (CMC) and nonclinical topics supports MaaT034's continued... ► Artikel lesen | |
| 07.10. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under Review | 315 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
07.10.2026 / 14:10 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 29.09. | MaaT Pharma Publishes its Half-Year 2026 Results and Provides a Business Update | 562 | Business Wire | MaaT013 (Xervyteg):
In September 2026, following the re-examination procedure, the CHMP maintained its negative opinion on the Conditional Marketing Authorization Application (MAA) for... ► Artikel lesen | |
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| 21.09. | MaaT Pharma Announces Upcoming Pre-IND Meeting with the FDA and Advances MaaT034 Toward Clinical Development in Solid Tumors | 517 | Business Wire | Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA), focused on CMC (Chemistry, Manufacturing, and Controls), is scheduled for October 2026, representing... ► Artikel lesen | |
| 18.09. | MaaT Pharma Provides Update on MaaT013 (Xervyteg) Potential Development Plan Following CHMP Negative Opinion After Re-examination | 645 | Business Wire | The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the Company's application for a Conditional Marketing Authorization... ► Artikel lesen | |
| 15.09. | MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg) Following Re-Examination for its Conditional Marketing Authorization Application in Europe | 504 | Business Wire | MaaT Pharma was informed of a negative trend during the Committee for Medicinal Products for Human Use (CHMP)'s Oral Explanation meeting which took place on September 14, 2026
Formal CHMP... ► Artikel lesen | |
| 06.07. | MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract | 424 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 02.07. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 495 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 30.06. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review | 404 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
30.06.2026 / 13:08 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 26.06. | EMA committee issues negative opinion on MaaT Pharma's MaaT013 | 5 | Investing.com | ||
| 26.06. | MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease | 1.176 | Business Wire | The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional Marketing Authorization Application (MAA) for MaaT013... ► Artikel lesen | |
| 11.06. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review | 349 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
11.06.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 26.05. | MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026 | 1.025 | Business Wire | MaaT013 (Xervyteg):
In May 2026, the Company was informed of a "negative trend" opinion on its Marketing Authorization Application from the Committee for Medicinal Products for Human Use... ► Artikel lesen | |
| 20.05. | MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg) in the treatment of acute Graft-versus-Host Disease | 1.002 | Business Wire | During the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) Oral Explanation, the Company received a "negative trend" opinion for the upcoming June... ► Artikel lesen | |
| 11.05. | MaaT Pharma to Hold Annual General Meeting on June 16, 2026 | 463 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 21.04. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy | 404 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
21.04.2026 / 15:09 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 01.04. | MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal | 600 | Business Wire | CHRONOS is one of the largest real-world studies including refractory GI-aGvHD patients (n=59) treated with third-line best available treatments other than microbiome-based therapy
Results... ► Artikel lesen | |
| 31.03. | MaaT Pharma Announces 2025 Annual Results and Provides Business Updates | 748 | Business Wire | Potential Pivotal Year for MaaT013 (Xervyteg):
Marketing Authorization Application (MAA) in Europe for MaaT013 (Xervyteg) submitted to the European Medicines Agency (EMA) in June 2025
... ► Artikel lesen | |
| 23.03. | MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation | 528 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 09.03. | MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management | 779 | Business Wire | Oral presentation during Presidential Plenary Session to feature the final results of the ARES pivotal Phase 3 trial evaluating MaaT013 in acute Graft-versus-Host Disease (aGvHD) with gastrointestinal... ► Artikel lesen |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 11,720 | +0,69 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026 | ||
| KUROS BIOSCIENCES | 22,760 | +0,80 % | Kuros Biosciences bekommt eine 3+: Warum unsere Experten noch nicht überzeugt sind - Dringend handeln! | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,517 | -0,40 % | Here's Why You Should Hold PacBio Stock in Your Portfolio for Now | ||
| MICROBOT MEDICAL | 1,020 | +3,24 % | Microbot Medical secures first office-based lab customer | ||
| BEONE MEDICINES LTD ADR | 334,00 | 0,00 % | BeOne Medicines Ltd.: BeOne präsentiert auf der ESMO 2026 überzeugende Daten zu schwer zu behandelndem Leber- und Lungenkrebs | Potenziell erster bispezifischer GPC3 x 4-1BB Antikörper seiner Klasse erzielt bei der Phase-3-Dosis eine bestätigte Ansprechrate von 36 und zeigt ein günstiges Sicherheitsprofil bei stark vorbehandeltem... ► Artikel lesen | |
| BIOMERIEUX | 89,55 | 0,00 % | bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026 | SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,065 | 0,00 % | Teva Completes Acquisition of BioXcel Assets, Expands Neuroscience Pipeline | ||
| PDS BIOTECHNOLOGY | 1,355 | +0,74 % | B.Riley hebt Kursziel für PDS Biotechnology nach Vorlage von Studiendaten an | ||
| BIO GREEN MED SOLUTION | 0,795 | 0,00 % | Morning Market Movers: Bio Green Med Solution, Solidion Technology, Indaptus Therapeutics, Merlin, Inc. See Big Swings | BEIJING (dpa-AFX) - At 7:20 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ANAPTYSBIO | 43,090 | -3,73 % | AnaptysBio, Inc.: Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update | Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growthPositive interim results from the pivotal AZUR-1 trial of Jemperli... ► Artikel lesen | |
| ZYMEWORKS | 26,010 | +1,05 % | Zymeworks Inc.: Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 | ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRa) expression levelsConfirmed objective response... ► Artikel lesen | |
| GENUS | 27,600 | -0,72 % | Genus-3-Polyeder: Mathematiker liefert Bauplan für komplexe Form mithilfe von ChatGPT | Es sieht aus wie ein Grafikfehler in einer 3D-Software, der beim Modellieren entsteht. Ein Mathematiker hat nun mit Unterstützung von KI bewiesen, dass hinter diesem vermeintlichen Chaos eine exakt... ► Artikel lesen | |
| AKESO | 9,630 | +1,56 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| MEIRAGTX | 8,500 | +2,41 % | MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting | ||
| XTL BIOPHARMACEUTICALS | 1,610 | +12,59 % | XTL Biopharmaceuticals Ltd.: XTL Completed the Acquisition of Psyga Bio Ltd. | expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a historic... ► Artikel lesen |
Das Unternehmen MAAT PHARMA SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,042 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAAT PHARMA SA finden Sie auf Wallstreet Online.